Jeff Huber

Mostafa Ronaghi

GRAIL, LLC

AgelessRx provides anti-aging treatments supported by longevity science. The organization offers various therapies to assist individuals in managing health concerns related to aging.

AgelessRx

Galleri Test

Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care.

We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges.

GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. 

For more information, please visit grail.com.

Community Guidelines: https://bit.ly/3xigb24 

6 Dimensions Capital

Ally Bridge Group

Sequoia Capital China

Blue Pool Capital

Genuity Science

Hillhouse Capital Group

China Merchants Securities

Canada Pension Plan Investment Board

Huangpu River Capital

PSP Investments

Illumina

GRAIL

GRAIL has been recognized on Fortune's 2023 #ChangeTheWorld list, as one of 50 companies driving positive social impact. 

This accomplishment is only possible due to the steadfast dedication of our employees, who are working together every day to redefine the status quo of cancer detection. Learn more: https://bit.ly/3ZB1KDu

This week GRAILers gathered to celebrate the upcoming #LunarNewYear. Best wishes and good fortune to all in the Year of the Dragon! 
#DiversityAndInclusion  

From addressing health disparities to advancing the science of cancer genomics, multi-cancer early detection has implications for many aspects of #cancer screening and care. We’re exploring the impacts of this technology on our podcast, The Cancer SIGNAL.

Subscribe here for new monthly episodes: https://bit.ly/42x1y9v

We’re excited to announce the name change of BIG (Black & Brown Influencers at GRAIL) in time for #BlackHistoryMonth! Anwell Wilbekin and Rich S.T Gilliam, co-leaders of BIG, unveil the new identity and outline upcoming events. We've curated insightful panel discussions on influence and health equity, along with a creative virtual paint night. Stay tuned for a month filled with celebration and empowerment at GRAIL! #DiversityAndInclusion #GRAILproud 

Proactive tools, like multi-cancer early detection tests, are helping people take more control of their health – but there’s more work to be done to help #CloseTheCareGap.

Ahead of #WorldCancerDay, we’re revisiting our podcast interview with Dr. Gary Puckrein, President and CEO of the National Minority Quality Forum, as he discusses how we can address barriers to equity in cancer screening. Hear more in this episode of #TheCancerSignal: https://bit.ly/49eqd5z 

Find us on all major podcast platforms:  
Apple: https://apple.co/3W0dso3  
Spotify: https://spoti.fi/3Kbe9Z8 
Google: https://bit.ly/3Fmp9j4 

Metric
Company Name	GRAIL, LLC	AgelessRx
Symbol	GRAL
MSH ID	COM:GRAIL	COM:AGELESSRX
Market	STOCKS	PRIVATE
Sector		Healthcare & Health Services
Industry		Medical Services
Country		US
Stage
Employee Count
Website		agelessrx.com
LinkedIn	grail-inc.
Founders

Metric
Market Cap	431.58M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	93.11M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-95.61M
EBITDA	-638.22M
Operating Income	-796.92M
Net Income	-1.47B
EPS	-47.20
Diluted EPS	-47.20
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-0.68
Operating Profit Margin	-7.63
EBITDA Margin	-6.85
Net Profit Margin	-8.90
Return on Equity	-0.10
Return on Assets	-0.10
Return on Capital Employed	-0.11

GRAL

COM:GRAIL

GRAIL

Last Close

33.45

07/03 21:00

Market Cap

431.58M

Beta: -

Volume Today

2.43M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.33
P/B Ratio	0.15
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	11.80
EV Multiple	-1.70

Metric
Days Sales Outstanding	149.72
Days Payables Outstanding	45.80
Days Inventory Outstanding	94.50
Operating Cycle	233.61
Cash Conversion Cycle	187.81
Asset Turnover	0.02

Metric
Operating Cash Flow	-595.80M
Free Cash Flow	-608.69M
Cash Flow to Debt	-4.73
Operating Cash Flow/Sales	-6.46
Free Cash Flow Yield	-0.70

Metric
Cash & Equivalents	97.29M
Accounts Receivable	-1.38M
Inventory	21.70M
Goodwill	888.94M
Debt to Capitalization	0.03
Debt to Assets	0.02
Current Ratio	1.88
Quick Ratio	11.26

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	-0.18
R&D to Revenue	4.04
SG&A to Revenue	2.26